{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.4","upperLimit":"27.3","value":"24.0"},{"groupId":"OG001","lowerLimit":"15.4","upperLimit":"25.6","value":"17.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"description":"Kaplan-Meier estimate of the median time from randomization to date of first observed progression of disease or death due to progression of disease (whichever comes first) for those participants with a best response of stable disease. Stable disease defined as neither sufficient shrinkage to qualify for a partial response nor sufficient increase to qualify for progressive disease taking as reference the nadir longest diameter since the treatment started, no unequivocal progression of existing non-target lesions, and no new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Panitumumab plus best supportive care (BSC). Panitumumab was administered by intravenous infusion at a dose of 6 mg/kg once every 2 weeks until participants developed progressive disease or were unable to tolerate study drug.","id":"OG000","title":"Panitumumab Plus BSC"},{"description":"Best supportive care defined as the best care available as judged appropriate by the investigator and according to institutional guidelines, including antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any symptomatic therapy as clinically indicated. For the purpose of this study, best supportive care does not include anti-neoplastic chemotherapy.","id":"OG001","title":"BSC Alone"}],"paramType":"MEDIAN","populationDescription":"Participants who had a best overall response of stable disease","reportingStatus":"POSTED","timeFrame":"From randomization until the data cutoff of 15 March 2007. The median follow-up time was 29.6 weeks in the panitumumab plus BSC group and 31.8 weeks in the BSC alone group.","title":"Duration of Stable Disease","type":"SECONDARY","unitOfMeasure":"weeks"}